MedPath

Technology of the radioisotopes for the intra-operative identification of the sentinel node in the premature gastric cancer. Clinical study of feasibility in order to improve the treatment and prognosis - ND

Conditions
gastric cancer
MedDRA version: 6.1Level: PTClassification code 10061968
Registration Number
EUCTR2006-001503-10-IT
Lead Sponsor
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
20
Inclusion Criteria

- Tis and T1 Early Gastric Cancer - T2 neoplasia that invades the muscular or serosa tunica Could be included in the study early tumors deal in inadequate way for endoscopica way to subject to surgical participation of radicalization
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- T3 tumor emerging to the serosa without invasion of contiguous organs - T4 tumor that infiltrates adjacent structures - M1

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To demonstrate the such clinical importance of methodical of intra-operative stage for the treatment of the premature gastric cancer.;Primary end point(s): Validation of the methodical;Secondary Objective: Realization of a diagnostic pre and intra-operating distance that uses the technology of the radioisotopes, for the identification of the metastases in the node in the premature gastric cancer. To guarantee the performance of one corrected operating procedure. To demonstrate to the high effectiveness accuracy and sensibility of the technology of the radioisotopes in the finding of the sentinel node in the premature gastric cancer. To demonstrate the determined superiority of the technology of the radioisotopes regarding that one of vital colouring for the identification of the sentinek node.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath